FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378952960> ?p ?o ?g. }

• W4378952960 endingPage "658" @default.
• W4378952960 startingPage "658" @default.
• W4378952960 abstract "Importance Anti–vascular endothelial growth factor (VEGF) agents are currently the mainstay of treatment for diabetic retinopathy (DR). Although effective, data on their systemic safety remains inconclusive, particularly in high-risk patient groups. Objective To explore the systemic safety of intravitreal anti-VEGF agents among patients with diabetes. Design, Setting, and Participants This was a retrospective, longitudinal population-based analysis of the Corporate Data Warehouse, a large-scale database of patients within the US Veteran Health Affairs. All patients 18 years and older with type 2 diabetes who were seen at any Veterans Affairs health care facility in the US between January 1, 2011, and December 31, 2012, were identified. Data were then extracted on incident systemic adverse events among this patient cohort from January 1, 2013, to December 31, 2017. All individuals with diabetes who did and did not receive anti-VEGF injections were included. Patients with a history of prior systemic adverse events and those who received an intravitreal injection between January 1, 2011, and December 31, 2012, were excluded. Data were analyzed from October 2019 to March 2023. Exposure Anti-VEGF injection. Main Outcomes and Measures Proportion of patients with any incident systemic adverse event, acute myocardial infarction, cardiovascular disease, or kidney disease at 1-, 3-, and 5-year follow-up. Results A total of 1 731 782 patients (mean [SD] age, 63.8 [12.3] years; 1 656 589 [95.7%] male) with type 2 diabetes were included. DR was present in 476 013 (27.5%), and 14 022 (0.8%) received anti-VEGF injections. Of the total number of patients with type 2 diabetes, 321 940 (18.6%) developed systemic adverse events between 2013 and 2017. The 5-year cumulative incidence of any systemic adverse event was 37.0% (5187/14 022) in the injection group vs 18.4% (316 753/1 717 760) in the noninjection group ( P &amp;lt; .001). Anti-VEGF injections were independently associated with a higher likelihood of developing any systemic adverse event (odds ratio, 1.8; 95% CI, 1.7-1.9) when controlling for age, race, sex, ethnicity, tobacco use, severity of DR, Deyo-Charlson Comorbidity Index score, mean hemoglobin A 1c , total number of injections, and statin use. Conclusion and Relevance In this study, intravitreal anti-VEGF injections were independently associated with a higher likelihood of systemic adverse events among patients with diabetes." @default.
• W4378952960 created "2023-06-02" @default.
• W4378952960 creator A5009464457 @default.
• W4378952960 creator A5010041931 @default.
• W4378952960 creator A5042264265 @default.
• W4378952960 creator A5050742471 @default.
• W4378952960 creator A5058782471 @default.
• W4378952960 creator A5070976237 @default.
• W4378952960 creator A5071879902 @default.
• W4378952960 date "2023-07-01" @default.
• W4378952960 modified "2023-10-17" @default.
• W4378952960 title "Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti–Vascular Endothelial Growth Factor Injections" @default.
• W4378952960 cites W1782108791 @default.
• W4378952960 cites W1809230663 @default.
• W4378952960 cites W1851754610 @default.
• W4378952960 cites W1915008606 @default.
• W4378952960 cites W1966632742 @default.
• W4378952960 cites W1972264330 @default.
• W4378952960 cites W1990031103 @default.
• W4378952960 cites W1991666098 @default.
• W4378952960 cites W2000445173 @default.
• W4378952960 cites W2012532020 @default.
• W4378952960 cites W2016121271 @default.
• W4378952960 cites W2017314392 @default.
• W4378952960 cites W2031891734 @default.
• W4378952960 cites W2041074255 @default.
• W4378952960 cites W2043836621 @default.
• W4378952960 cites W2064159363 @default.
• W4378952960 cites W2075442945 @default.
• W4378952960 cites W2083352049 @default.
• W4378952960 cites W2090359115 @default.
• W4378952960 cites W2096134439 @default.
• W4378952960 cites W2096547439 @default.
• W4378952960 cites W2102463203 @default.
• W4378952960 cites W2109045647 @default.
• W4378952960 cites W2121785313 @default.
• W4378952960 cites W2123629654 @default.
• W4378952960 cites W2124348055 @default.
• W4378952960 cites W2124377399 @default.
• W4378952960 cites W2126946832 @default.
• W4378952960 cites W2129168200 @default.
• W4378952960 cites W2146094308 @default.
• W4378952960 cites W2165047966 @default.
• W4378952960 cites W2200657718 @default.
• W4378952960 cites W2337004113 @default.
• W4378952960 cites W2503745853 @default.
• W4378952960 cites W2578241329 @default.
• W4378952960 cites W2616361514 @default.
• W4378952960 cites W2621341424 @default.
• W4378952960 cites W2669540614 @default.
• W4378952960 cites W2766278264 @default.
• W4378952960 cites W2791776334 @default.
• W4378952960 cites W2883798682 @default.
• W4378952960 cites W2895211690 @default.
• W4378952960 cites W2906276356 @default.
• W4378952960 cites W2913311753 @default.
• W4378952960 cites W2937282237 @default.
• W4378952960 cites W2991540252 @default.
• W4378952960 cites W2997341807 @default.
• W4378952960 cites W3156078512 @default.
• W4378952960 cites W4229077009 @default.
• W4378952960 cites W4230156157 @default.
• W4378952960 cites W922383587 @default.
• W4378952960 cites W2026443681 @default.
• W4378952960 doi "https://doi.org/10.1001/jamaophthalmol.2023.2098" @default.
• W4378952960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37261816" @default.
• W4378952960 hasPublicationYear "2023" @default.
• W4378952960 type Work @default.
• W4378952960 citedByCount "3" @default.
• W4378952960 countsByYear W43789529602023 @default.
• W4378952960 crossrefType "journal-article" @default.
• W4378952960 hasAuthorship W4378952960A5009464457 @default.
• W4378952960 hasAuthorship W4378952960A5010041931 @default.
• W4378952960 hasAuthorship W4378952960A5042264265 @default.
• W4378952960 hasAuthorship W4378952960A5050742471 @default.
• W4378952960 hasAuthorship W4378952960A5058782471 @default.
• W4378952960 hasAuthorship W4378952960A5070976237 @default.
• W4378952960 hasAuthorship W4378952960A5071879902 @default.
• W4378952960 hasConcept C126322002 @default.
• W4378952960 hasConcept C134018914 @default.
• W4378952960 hasConcept C141071460 @default.
• W4378952960 hasConcept C167135981 @default.
• W4378952960 hasConcept C197934379 @default.
• W4378952960 hasConcept C2775969662 @default.
• W4378952960 hasConcept C2777180221 @default.
• W4378952960 hasConcept C2778653478 @default.
• W4378952960 hasConcept C2779829184 @default.
• W4378952960 hasConcept C2908647359 @default.
• W4378952960 hasConcept C50440223 @default.
• W4378952960 hasConcept C555293320 @default.
• W4378952960 hasConcept C71924100 @default.
• W4378952960 hasConcept C72563966 @default.
• W4378952960 hasConcept C99454951 @default.
• W4378952960 hasConceptScore W4378952960C126322002 @default.
• W4378952960 hasConceptScore W4378952960C134018914 @default.
• W4378952960 hasConceptScore W4378952960C141071460 @default.
• W4378952960 hasConceptScore W4378952960C167135981 @default.
• W4378952960 hasConceptScore W4378952960C197934379 @default.

• next